Diclofenac for advanced lung cancer on immunotherapy
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests whether adding the anti-inflammatory drug diclofenac can help people with advanced non-small cell lung cancer whose tumors are growing while on a single immunotherapy drug. You must have been on immunotherapy for at least 12 weeks and have a growing tumor, but your doctor does not plan to change your treatment right away.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older with stage 3 or 4 non-small cell lung cancer that has spread.
- You have been on a single immunotherapy drug (like Keytruda or Tecentriq) for at least 12 weeks.
- You have at least one tumor that is growing, but your doctor says you can continue your current immunotherapy for now.
- You can take pills by mouth and have adequate kidney, liver, and blood cell counts.
- You are not on blood thinners or aspirin, and you do not have conditions that prevent you from taking NSAIDs (like stomach ulcers or kidney disease).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new experimental drug called PF-08046054/SGN-PDL1V against a standard chemotherapy (docetaxel) for people with a type of advanced lung cancer that has PD-L1 protein on at least 1% of tumor cells and has progressed after prior treatments. The goal is to see if the new drug works better or has fewer side effects.
This study tests a combination of chemotherapy and immunotherapy in people with advanced non-small cell lung cancer that has spread or cannot be removed with surgery. The goal is to see how well this treatment works in patients with different levels of daily activity.
This trial tests a new study drug called PF-08634404 combined with standard chemotherapy for people with advanced lung cancer that has not been treated before. It aims to see if this combination works better than chemotherapy alone.
This trial is comparing a new combination of two immunotherapy drugs (nivolumab and relatlimab) plus chemotherapy against the standard immunotherapy (pembrolizumab) plus chemotherapy for people with advanced non-squamous non-small cell lung cancer that has a certain protein (PD-L1) on at least 1% of its cells. The goal is to see if the new combination works better.
This Phase 2 study tests whether adding envafolimab (an immunotherapy) to docetaxel—sometimes with another drug—can improve outcomes in advanced non-small cell lung cancer (NSCLC). It focuses on people whose cancer has already gotten worse after platinum chemotherapy plus a PD-1–based treatment.
This trial tests a new drug called cadonilimab combined with chemotherapy for people with advanced lung cancer who have already tried and failed immunotherapy. It aims to see if this combination can help when standard immunotherapy no longer works.
Hear when a new Advanced Lung Non-Small Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.